Log in to save to my catalogue

Patients lacking classical poor prognostic markers might also benefit from a step-down glucocorticoi...

Patients lacking classical poor prognostic markers might also benefit from a step-down glucocorticoi...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4422551

Patients lacking classical poor prognostic markers might also benefit from a step-down glucocorticoid bridging scheme in early rheumatoid arthritis: week 16 results from the randomized multicenter CareRA trial

About this item

Full title

Patients lacking classical poor prognostic markers might also benefit from a step-down glucocorticoid bridging scheme in early rheumatoid arthritis: week 16 results from the randomized multicenter CareRA trial

Publisher

England: BioMed Central Ltd

Journal title

Arthritis research & therapy, 2015-04, Vol.17 (1), p.97-97, Article 97

Language

English

Formats

Publication information

Publisher

England: BioMed Central Ltd

More information

Scope and Contents

Contents

Considering a lack of efficacy data in patients with early rheumatoid arthritis (eRA) presenting without classical markers of poor prognosis, we compared methotrexate (MTX) with or without step-down glucocorticoids in the CareRA trial.
Disease-modifying antirheumatic drug-naïve patients with eRA were stratified into a low-risk group based on pro...

Alternative Titles

Full title

Patients lacking classical poor prognostic markers might also benefit from a step-down glucocorticoid bridging scheme in early rheumatoid arthritis: week 16 results from the randomized multicenter CareRA trial

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4422551

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4422551

Other Identifiers

ISSN

1478-6354

E-ISSN

1478-6354,1478-6362

DOI

10.1186/s13075-015-0611-8

How to access this item